Ronald J McPherson1, Sandra E Juul. 1. Department of Pediatrics, Division of Neonatology, University of Washington, Seattle, USA.
Abstract
PURPOSE OF REVIEW: Perinatal asphyxia, intraventricular hemorrhage and stroke are common causes of neonatal brain injury, with hypoxia-ischemia as the final common pathway of injury. Erythropoietin (Epo) has potential to lessen neurologic sequelae due to hypoxia-ischemia. The purpose of this review is to highlight new clinical trials and experimental evidence that expand our understanding of Epo as a potential treatment for perinatal brain injury. RECENT FINDINGS: Several trials of Epo treatment are reviewed: two phase I/II trials of high-dose Epo given to preterm infants established pharmacokinetic and safety profiles, and a trial of Epo treatment for term infants with moderate hypoxic-ischemic encephalopathy found reduced disability. Potential risks and benefits of high-dose Epo are discussed. New evidence related to Epo receptor expression, signal transduction pathways, and mechanisms of neuroprotection are reviewed. SUMMARY: Cautious optimism is warranted regarding the use of high-dose Epo as a treatment option for neonatal brain injury. To date, Epo has been well tolerated to use in neonatal populations and now studies of neuroprotective efficacy are underway.
PURPOSE OF REVIEW: Perinatal asphyxia, intraventricular hemorrhage and stroke are common causes of neonatal brain injury, with hypoxia-ischemia as the final common pathway of injury. Erythropoietin (Epo) has potential to lessen neurologic sequelae due to hypoxia-ischemia. The purpose of this review is to highlight new clinical trials and experimental evidence that expand our understanding of Epo as a potential treatment for perinatal brain injury. RECENT FINDINGS: Several trials of Epo treatment are reviewed: two phase I/II trials of high-dose Epo given to preterm infants established pharmacokinetic and safety profiles, and a trial of Epo treatment for term infants with moderate hypoxic-ischemicencephalopathy found reduced disability. Potential risks and benefits of high-dose Epo are discussed. New evidence related to Epo receptor expression, signal transduction pathways, and mechanisms of neuroprotection are reviewed. SUMMARY: Cautious optimism is warranted regarding the use of high-dose Epo as a treatment option for neonatal brain injury. To date, Epo has been well tolerated to use in neonatal populations and now studies of neuroprotective efficacy are underway.
Authors: Matthew J Girgenti; Joshua Hunsberger; Catharine H Duman; Monica Sathyanesan; Rose Terwilliger; Samuel S Newton Journal: Biol Psychiatry Date: 2009-01-29 Impact factor: 13.382
Authors: Lauren Fletcher; Sanjivan Kohli; Shane M Sprague; Robert A Scranton; Stuart A Lipton; Augusto Parra; David F Jimenez; Murat Digicaylioglu Journal: J Neurosurg Date: 2009-07 Impact factor: 5.115
Authors: Pascal E Sanchez; Fabrice P Navarro; Raafat P Fares; Jérémie Nadam; Béatrice Georges; Colette Moulin; Marion Le Cavorsin; Chantal Bonnet; Philippe Ryvlin; Amor Belmeguenai; Jacques Bodennec; Anne Morales; Laurent Bezin Journal: J Comp Neurol Date: 2009-06-01 Impact factor: 3.215
Authors: Shenandoah Robinson; Christopher J Corbett; Jesse L Winer; Lindsay A S Chan; Jessie R Maxwell; Christopher V Anstine; Tracylyn R Yellowhair; Nicholas A Andrews; Yirong Yang; Laurel O Sillerud; Lauren L Jantzie Journal: Exp Neurol Date: 2017-12-26 Impact factor: 5.330
Authors: Thomas Wood; Daniel Moralejo; Kylie Corry; Jessica M Snyder; Christopher Traudt; Chad Curtis; Elizabeth Nance; Pratik Parikh; Sandra E Juul Journal: Dev Neurosci Date: 2019-05-10 Impact factor: 2.984
Authors: Christopher M Traudt; Ronald J McPherson; Larry A Bauer; Todd L Richards; Thomas M Burbacher; Ryan M McAdams; Sandra E Juul Journal: Dev Neurosci Date: 2013-11-01 Impact factor: 2.984
Authors: Yvonne W Wu; Larry A Bauer; Roberta A Ballard; Donna M Ferriero; David V Glidden; Dennis E Mayock; Taeun Chang; David J Durand; Dongli Song; Sonia L Bonifacio; Fernando F Gonzalez; Hannah C Glass; Sandra E Juul Journal: Pediatrics Date: 2012-09-24 Impact factor: 7.124